


Amendments to the Claims

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of formula I



wherein

R_1 is C_{1-6} alkyl optionally substituted by OH, C_{1-2} alkoxy or 1 to 6 fluorine atoms, C_{2-6} alkenyl; or C_{2-6} alkynyl methyl;

R_2 is a residue of formula (c)



wherein

Y' is a direct bond, O, CO, CHOH or $C=NOR_6$ wherein R_6 is H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl or benzyl;

n is 0, 1, 2, 3, 4 or 5;


m is 0, 1, 2, 3, 4, 5 or 6, provided that the sum of $n+m$ is 3-8;

each of p and q , independently, is 0, 1, 2 or 3; with the proviso that $p+q=3$;

the chain $(CH_2)_n-(CF_2)_m-CHpFq$ being optionally interrupted by one carbon-carbon double or triple bond, one CO or one or two oxygen atoms R_2' or R_2''


wherein R_2' is X_1 , $O-X_1$, $CO-X_1$, $CH(OH)-X_1$, $C(NOR_6)-X_1$, $S-X_1$, $SO-X_1$, SO_2-X_1 or $N(C_{1-6}\text{alkyl})-X_1$ wherein X_1 is C_{3-8} alkyl substituted by 1 to 17 fluorine atoms and optionally interrupted in the carbon chain by one or more O, $C=O$, $CH-OH$ or $C=NOR_6$ and/or one carbon-carbon double or triple bond; pentyl substituted by C_{1-3} alkyl and optionally interrupted in the carbon chain by one or more O, $C=O$, $CH-OH$ or $C=NOR_6$ and/or one carbon-carbon double or triple bond; C_{2-8} alkyl- C_{3-6} cycloalkyl wherein the C_{2-8} alkyl moiety is optionally interrupted in the carbon chain by one or more O, $C=O$, $CH-OH$ or $C=NOR_6$ and/or one carbon-carbon double or triple bond, and the C_{3-6} cycloalkyl and/or the C_{2-8} alkyl is substituted by 1 to 17 fluorine atoms; and each of R_6 , independently, is H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl or benzyl; and

and wherein R_2'' is $X-CH_2-CH_2-R$ attached in position para, wherein X is O, CH_2 , or $C=O$; and R is a residue of formula (b)



wherein each of R_7 to R_{11} , independently, is H; Cl; Br; F; CN; CF_3 ; OCF_3 ; $OCHF_2$; C_{1-6} alkyl; C_{1-6} alkoxy; C_{3-6} cycloalkyl; C_{3-6} cycloalkoxy; acyl; or optionally substituted phenyl; or R_9 and R_{10} form together 3,4- $[O(CH_2)_rO]$ wherein r is 1 or 2; or (R_7 and R_8) or (R_8 and R_9) together with the carbon atoms to which they are attached, form a fused cyclic or heterocyclic ring and the remaining R_9 to R_{11} , or R_7 and R_{10} and R_{11} , respectively, are as defined above; or R is α - or β -naphthyl optionally substituted by one to 5 substituents as defined above for R_7 to R_{11} ;

R_3 is $Z-X_2$ wherein Z is CH_2 , CHF or CF_2 or CHMe and X_2 is OH or a residue of formula (a)



wherein Z_1 is a direct bond, CH_2 , CHF, CF_2 or O, and each of R_{12} and R_{13} , independently, is H or C_{1-4} alkyl optionally substituted by 1, 2 or 3 halogen atoms; and each of R_4 and R_5 , independently, is H, C_{1-4} alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl in free form or in salt form.

2. (Currently Amended) A compound according to claim 1 wherein R_2 is R_2' which is $X_1-O-X_1-CO-X_1-CH(OH)-X_1$ or $-C(NOR_6)-X_1$ is selected from the group consisting of:

$-Y-C_nF_{2n+1}$ wherein $n=3-8$ and Y is CH_2 , O or $C=O$;

$-Y-CH_2C_nF_{2n+1}$ wherein $n=1-7$ and Y is CH_2 , O or $C=O$;

$-Y-CH_2CH_2C_nF_{2n+1}$ wherein $n=1-6$ and Y is CH_2 , O or $C=O$;

$-Y-CH_2CH_2CH_2C_nF_{2n+1}$ wherein $n=1-5$ and Y is CH_2 , O or $C=O$;

$-Y-(CH_2)_nF$ wherein $n=1-7$ and Y is CH_2 , O or $C=O$;

$-Y-(CH_2)_nCF_3$ wherein $n=1-6$ and Y is CH_2 , O or $C=O$;

$-Y-(CH_2)_nCF_2CH_3$ wherein $n=1-4$ and Y is CH_2 , O or $C=O$;

$-Y-(CH_2)_n(CF_2)_mCHF_2$ wherein $n=0-3$, $m=1-6$, $n+m=3-7$ and Y is CH_2 , O or $C=O$; and

$-Y-(CH_2)_nC(O)CF_3$ wherein $n=1-5$ and Y is CH_2 , O or $C=O$.

3.-7. (Canceled)

8. (Previously Presented) A pharmaceutical composition comprising a compound according claim 1, or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier therefor.

9. (Previously Presented) A pharmaceutical combination comprising a compound according to claim 1, in free form or in pharmaceutically acceptable salt form, and at least one co-agent selected from an immunosuppressant agent, an immunomodulatory agent, and anti-inflammatory or chemotherapeutic drug.

10. (Previously Presented) A method for treating disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases in a subject comprising administering to the subject in need thereof an effective amount of a compound according claim 1, or a pharmaceutically acceptable salt thereof.

11.-19. (Canceled)